Spotlight on Amanda Paulovich

Vision for the Future

Amanda Paulovich, Oncologist and Cancer Geneticist

It took only a few stray cancer cells to direct Dr. Amanda Paulovich's research path.

While training in both clinical medicine and basic science, she treated oncology patients who appeared cured after treatment, but the best of scans couldn't detect a small number of cells that sometimes escaped the original cancer site. Those renegade cells went on to become hard-to-stop metastatic cancer.

"The reality of how difficult it is to treat a tumor once even a few cells have escaped the primary site was quite overwhelming," she said. "It made me realize how so few cells could make our treatments largely ineffective."

The quest for Paulovich became — and remains — to find miniscule molecules in the body in order to diagnose and eliminate cancer long before it becomes a tumor or errant cells.

Dr. Amanda Paulovich
Dr. Amanda Paulovich, a professor in Fred Hutch's Translational Science and Therapeutics Division, was motivated by an "ethical dilemma" to research how proteins affect the way cancer patients react to cancer drugs. Robert Hood / Fred Hutch

This promising field of biomarker discovery is in its infancy. The challenge and potential of such work led Paulovich to Fred Hutch in 2004 to direct its early detection research.

Genes instruct cells, and proteins do the work that drives both cellular health and disease. Genomics is the study of gene sequences; proteomics analyzes proteins.

So while genes hint at the likelihood of developing a certain disease, proteins show what is currently happening in a patient. The discovery that proteins are leaked by tumors into the blood and urine could lead to better diagnostic tools for cancer detection.

Thousands of potential biomarkers have been discovered, and this list continues to grow. But the sobering reality is that very few of these candidates have been validated, and even fewer have reached patients.

Paulovich's lab is developing technologies to rapidly screen large numbers of candidate protein biomarkers in the hundreds of patient samples necessary for verification. Identifying these key biomarkers has disease implications far beyond cancer.

"The idea behind personalized medicine is figuring out what's the ideal intervention for you, which will cut costs and improve our treatments — that's the ultimate goal."

Paulovich and her colleagues recently took a big step forward in overcoming limiting factors validating biomarkers for clinical use: a lack of standardized technologies and methodologies.

A national scientific network that includes Paulovich's team may have solved that dilemma by creating a new method for detecting and quantifying protein biomarkers in body fluids.

This novel approach holds the promise of ensuring that only the strongest biomarker candidates will advance down the development pipeline.

"If the technologies meet their potential, we'll stop treating patients based on population averages," said Paulovich, who holds the Aven Foundation Endowed Chair. "The idea behind personalized medicine is figuring out what's the ideal intervention for you, which will cut costs and improve our treatments — that's the ultimate goal. If we can make it work, it will have a giant impact."

There are already examples of this approach in lung and breast cancer treatments. "It's just a matter of making what are now the exceptions, the rule," she said. "I think we're only a decade or two away."

— Updated October 3, 2023


Researcher News

All news
Big-picture approach helps identify experimental diagnostic to personalize ovarian cancer treatment Team uses large-scale proteogenomic changes to identify which patients should look beyond standard treatment options August 3, 2023
Omics made easier To see the big picture, just add ‘ome’ March 30, 2021
Scientists predict progress against COVID-19, cancer in 2021 After a challenging and deadly 2020, some hopeful predictions for the new year December 22, 2020
A path opens for precise analyses of breast cancer proteins Paulovich lab runs CLIA-cleared tests to find patients appropriate for new HER2-targeted therapies July 27, 2020